Expert Interviews

The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.

The GOLD report committee member highlights advances in knowledge of COPD phenotypes and the new role for biologic medications in this year's video series.

Hopkins, of the National Foundation for Infectious Diseases, is frustrated by the diminished societal response to the virus' circulation including ongoing low vaccination rates.

Donna Ryan, MD, highlights how the media has helped to reframe obesity as a chronic disease and how antiobesity drugs are transforming metabolic disease treatment.

Donna Ryan, MD, discusses the most significant clinical trials published this year in the field of obesity medicine.

Panelists discuss key insights on the importance of early screening for T1D, the role of antibody testing in identifying at-risk individuals, and the need for timely intervention to preserve ß-cell function and optimize long-term management strategies for better patient outcomes.

Panelists discuss how teplizumab infusion requires specialized medical facilities equipped to manage intravenous therapy, monitor for potential adverse effects, and provide appropriate care during treatment to ensure patient safety and efficacy.

Panelists discuss how teplizumab, an anti-CD3 monoclonal antibody, delays the onset and progression of type 1 diabetes by modulating immune response and preserving ß-cell function in high-risk individuals.

Panelists discuss screening for T1D for individuals at higher risk, such as those with a family history of T1D, autoimmune conditions, or certain genetic markers, to identify early signs of the disease and enable timely intervention.

Panelists discuss how antibody screening tests for type 1 diabetes (T1D), including tests for insulin autoantibodies (IAA), glutamic acid decarboxylase (GAD) antibodies, and other markers can help identify individuals at risk for developing the disease before clinical symptoms appear, enabling earlier monitoring and potential intervention.